Consensus report: clinical recommendations for the prevention and management of the nocebo effect in biosimilar-treated IBD patients.

Date publication

mai 2019

Journal

Alimentary pharmacology & therapeutics

Auteurs

Membres identifiés du Cancéropôle Est :
Pr PEYRIN-BIROULET Laurent

Tous les auteurs :
Pouillon L, Danese S, Hart A, Fiorino G, Argollo M, Selmi C, Carlo-Stella C, Loeuille D, Costanzo A, Lopez A, Vegni E, Radice S, Gilardi D, Socha M, Fazio M, González-Lorenzo M, Bonovas S, Magro F, Peyrin-Biroulet L

Lien Pubmed

https://www.ncbi.nlm.nih.gov/pubmed/30932219

Résumé

The nocebo effect is a negative effect of a pharmacological or nonpharmacological medical treatment that is induced by patients' expectations, and that is unrelated to the physiological action of the treatment. The nocebo effect can negatively affect treatment outcomes.

Mots clés

Biosimilar Pharmaceuticals, therapeutic use, Consensus, Europe, Humans, Inflammatory Bowel Diseases, drug therapy, Italy, Nocebo Effect, Practice Guidelines as Topic, Secondary Prevention, methods, Treatment Outcome

Référence

Aliment Pharmacol Ther. 2019 05;49(9):1181-1187